Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.02.033 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Tingrui Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Medical Guarantee Center, Second Affiliated Hospital o…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 413 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) is a highly specific anti-tumor immunotherapy that has shown promise in the treatment of hematological malignancies. However, there has been a slow progress toward the treatment of solid tumors owing to the complex tumor microenvironment that affects the localization and killing ability of the CAR cells. Solid tumors with a strong immunosuppressive microenvironment and complex vascular system are unaffected by CAR cell infiltration and attack. To improve their efficacy toward solid tumors, CAR cells have been modified and upgraded by "decorating" and "pruning". This review focuses on the structure and function of CARs, the immune cells that can be engineered by CARs and the transformation strategies to overcome solid tumors, with a view to broadening ideas for the better application of CAR cell therapy for the treatment of solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China; School of Medicine…
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Shanghai Engineering Research Center for Topical Chinese Medicine, Shanghai 200443, China; Department of Pharmacy, First Aff…
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; Shanghai Engineering Research Center for Topical Chinese Medicine, Shanghai 200443, China.
- School of Medicine, Shanghai University, Shanghai 200444, China.
- Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China. Electronic address: wh7975@163.com.
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai 200443, China; School of Medicine, Shanghai University, Shanghai 200444, China; Shanghai Engineering Research Center for Topical Chinese Me…
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Zhang, T., Tai, Z., Miao, F., Zhang, X., Li, J., Zhu, Q., Wei, H., & Chen, Z. (2024). Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.033
Vancouver
Zhang T, Tai Z, Miao F, Zhang X, Li J, Zhu Q, et al. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.033
BibTeX
@article{Zhang2024,
author = {Zhang, Tingrui and Tai, Zongguang and Miao, Fengze and Zhang, Xinyue and Li, Jiadong and Zhu, Quangang and Wei, Hua and Chen, Zhongjian},
title = {Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.02.033}
}
EUVIMED